MedTrace Logo

Clinical Evaluation of Furocyst in Patients With Poly Cystic Ovary Syndrome

NCT02789488 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2016-06-03

No results posted yet for this study

Summary

Poly cystic ovary syndrome (PCOS) is a disease which is prevalent in women of reproductive age facing obesity along with increased risk of type-2 diabetes and high cholesterol levels. The genetically determined cause of the PCOS includes disturbed levels of insulin and androgens. Standardized fenugreek seed extract (Furocyst) contains compounds such as saponins \& flavonoids which act on the insulin and indirectly helps to regulate the androgen levels in the body.

Conditions

  • Poly Cystic Ovary Syndrome

Interventions

DIETARY_SUPPLEMENT

Fenugreek seeds extract 500 mg

Furocyst one caps BID

Sponsors & Collaborators

  • Chemical Resources

    lead INDUSTRY

Principal Investigators

  • Dr Amrita Sarkari Jaipuriar, MS · Garg Hospital,Goalghar .Gorakhpur,UP,India

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2014-07-31
Completion
2014-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02789488 on ClinicalTrials.gov